

RESEARCH ARTICLE

Cancer Genetics and Epigenetics

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance

José Manuel Sánchez-Maldonado^{1,2,3} | Angelica Macaudo³ |
 Antonio José Cabrera-Serrano^{1,2} | Hauke Thomsen⁴ | Murat Güler^{3,5} |
 Rob Ter Horst^{6,7} | Bethany van Guelpen^{8,9}  | Pavel Vodicka^{10,11,12} |
 Stefano Landi¹³  | Subhayan Chattopadhyay¹⁴ | Pelin Ünal³ |
 Lucía Ruiz-Durán^{1,2} | Delphine Casabonne^{15,16}  | Hartmut Goldschmidt¹⁷ |
 Istemi Serin¹⁸ | María Carretero-Fernández^{1,2} | Elena Cabezudo^{19,20} |
 Fernando Reyes-Zurita²¹ | Aaron D. Norman²² | Ramón García-Sanz²³ |
 Gabriele Capurso^{24,25} | Per Hoffmann^{26,27} | Ulrika Pettersson-Kymmer²⁸ |
 Francisco Jiménez-Romera^{1,2} | S. Vincent Rajkumar²⁹ | Niels Weinhold³⁰ |
 Ludmila Vodickova^{10,11,12} | Christian Langer³¹ | Angelika Stein³ |
 Abdulkadir Karismaz³² | Victor Moreno^{33,34,35,36}  | Markus M. Nöthen²⁶ |
 Karl-Heinz Jöckel³⁷ | Francesca Tavano³⁸  | Joaquín Martínez-López³⁹ |
 Shaji K. Kumar²⁹ | Juan Francisco Gutiérrez-Bautista^{2,40,41} | Daniela Basso⁴² |
 Florentin Späth⁴³ | Yolanda Benavente^{15,16,44} | Michelle A. T. Hildebrandt⁴⁵  |
 Börge Schmidt³⁷  | Tereza Sevcikova^{46,47} | Rui Manuel Vieira Reis^{48,49}  |
 Yang Li^{6,50} | Miguel Ángel López-Nevot^{2,40,41} | Mihai G. Netea^{6,51} |
 Daniele Campa¹³  | Alyssa Clay-Gilmour⁵² | Susan L Slager⁵³ |
 Kari Hemminki^{54,55} | Celine M Vachon²⁰ | Asta Försti^{56,57}  |
 Federico Canzian³  | Juan Sainz^{1,2,16,21} 

Abbreviations: 500FG, 500 Functional Genomics; AL, amyloid light-chain amyloidosis; ARF, Alternative Reading Frame; BBMRI-NL, Biobanking and Biomolecular Resources Research Infrastructure—Netherlands; BMBF, German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung); cQTL, cytokine quantitative trait locus; CRAB, hypercalcemia, renal insufficiency, anemia, bone lesions; DKFZ, German Cancer Research Center (Deutsches Krebsforschungszentrum); eQTL, expression quantitative trait locus; ERDF, European Regional Development Fund; GWAS, genome-wide association study; HFGP, Human Functional Genomics Project; HWE, Hardy–Weinberg equilibrium; IBERICAT, Iberian Multiple Myeloma and MGUS Study; ICD, International Classification of Diseases; IMMESE, International Multiple Myeloma rEsearch Consortium; IRB, Institutional Review Board; LD, linkage disequilibrium; LOCO, leave-one-chromosome-out; MAC, minor allele count; MAF, minor allele frequency; MDE, myeloma-defining events; MDM, monocyte-derived macrophages; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; OR, odds ratio; PBMC, peripheral blood mononuclear cell; QC, quality control; SNP, single nucleotide polymorphism; SPA, saddle-point approximation; UKBB, UK Biobank; WB, whole blood.

José Manuel Sánchez-Maldonado, Angelica Macaudo, and Antonio José Cabrera-Serrano contributed equally to this work.

For affiliations refer to page 9

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2026 The Author(s). *International Journal of Cancer* published by John Wiley & Sons Ltd on behalf of UICC.

Correspondence

Juan Sainz, Department of Biochemistry and Molecular Biology, Faculty of Sciences, University of Granada, Avenida de Fuente Nueva, s/n, 18071, Granada, Spain.
Email: jsainz@ugr.es

Funding information

European Union's Horizon 2020 research and innovation programme, Grant/Award Number: 856620; Consejería de Transformación Económica, Industria, Conocimiento y Universidades and FEDER, Grant/Award Number: PY20/01282; Dietmar Hopp Foundation, and the German Ministry of Education and Science, Grant/Award Number: BMBF: CLIMMICS [01ZX1309]; CRIS Foundation against cancer, the Cancer Network of Excellence, Grant/Award Number: RD12/10Red de Cáncer; SALVAGE, Grant/Award Number: CZ.02.01.01/00/22_008/0004644; National Cancer Institute of the National Institutes of Health, Grant/Award Numbers: R01CA186646, U01CA249955, U01CA271014; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), action Genrisk; Italian Ministry of Health through the Ricerca Corrente program 2025-2027; Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia, Grant/Award Number: 2021SGR01354; Instituto de Salud Carlos III, Grant/Award Numbers: CIBERESP CB06/02/0073, DTS23/00030, FI21/00090, PI17/02256, PI20/00288, PI20/01845; Universidad de Granada/CBUA

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a necessary precursor condition to multiple myeloma (MM). Given the role of autophagy in modulating MM risk, we investigated whether genetic variation in autophagy-related genes influences susceptibility to MGUS. We analyzed the association of 34,042 common autophagy-related single nucleotide polymorphisms (SNPs) with MGUS across six independent cohorts, five from Europe and one from North America, comprising 2317 MGUS cases and 282,358 controls. We also assessed their impact on immune parameters, including absolute counts of 91 blood-derived immune cell subsets and 103 circulating immunological proteins. Meta-analysis revealed a genome-wide significant association between the *ULK4*_{rs6599175C} allele and increased MGUS risk ($p = 3.35 \times 10^{-8}$). Carriers of this allele showed reduced counts of memory B cell subsets (IgM+CD38+CD27+ and IgD+IgM+CD27+; $p = .0038$ and $p = .0056$, respectively) and natural effector B cells (CD24+CD38+IgD+IgM+ cells; $p = .0060$). Although these associations were not statistically significant after multiple testing correction, they suggest a role of *ULK4* in early B-cell differentiation. Additionally, the *CDKN2A*_{rs2811710} variant showed a suggestive association with MGUS risk ($p = 2.17 \times 10^{-4}$), affecting transcription factor binding involved in B-cell proliferation and differentiation, although it lacked association with immune markers. In conclusion, we confirm a genome-wide significant association of the *ULK4* locus and MGUS risk, supporting its role in early B-cell differentiation, and identify *CDKN2A* as a candidate susceptibility locus warranting further investigation.

KEYWORDS

autophagy, blood-derived cell populations, genetic variants, MGUS, susceptibility

What's New?

Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor to multiple myeloma, sharing substantial genetic features with overt malignancy. Given evidence implicating autophagy in myeloma risk, this study examined whether genetic variations in autophagy-related genes influence MGUS susceptibility. Using large-scale genome-wide association meta-analysis integrated with immunogenomic data, the authors identified an association between MGUS risk and *ULK4*, which encodes a serine/threonine kinase involved in various biological processes. A variant of *CDKN2A* was additionally identified as a candidate susceptibility locus. The findings highlight genetic factors that potentially contribute to autophagy pathways and early B-cell differentiation in plasma cell disorders.

1 | INTRODUCTION

Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic, pre-malignant plasma cell disorder defined by the presence of fewer than 10% clonal plasma cells in the bone marrow, serum monoclonal (M-) protein levels below 3 g/dL, and the absence of myeloma-defining end-organ damage such as hypercalcemia, renal insufficiency, anemia, or lytic bone lesions.¹⁻³ As patients with MGUS do not meet CRAB criteria or exhibit myeloma-defining events (MDE), routine surveillance is essential to detect disease evolution. MGUS is

relatively common in adults over the age of 50, with a prevalence of 3%–4% and carries an annual risk of progression to multiple myeloma (MM) of approximately 1%.^{2,4}

MGUS is a precursor to several malignant or systemic conditions, including MM, light chain amyloidosis, lymphoplasmacytic lymphoma, and Waldenström macroglobulinemia.⁵⁻⁷ Risk stratification models divide MGUS into low- and high-risk categories based on clinical and biochemical parameters, informing follow-up schedules: patients with high-risk profiles require annual evaluation, often for life or until progression.⁸ Understanding susceptibility to

MGUS requires an integrated view of genetic predisposition, environmental exposures, immune function, and demographic factors. Established non-modifiable risk factors include older age, male sex, African ancestry, and family history of monoclonal gammopathies.⁹ Prevalence estimates vary geographically from 0.24% to 9%, reflecting the interplay of genetic background, environmental influences, and differences in healthcare access.¹⁰ Modifiable factors such as chronic immune stimulation (due to infections or autoimmune disorders) and occupational exposure to substances like asbestos, pesticides, or industrial chemicals may also contribute to disease onset.^{10,11}

At the genetic level, MGUS shares substantial overlap with MM.^{12,13} Genome-wide association studies (GWAS) have identified some single-nucleotide polymorphisms (SNPs) associated with MGUS risk.^{14–17} Polygenic risk scores built on MM-associated loci show predictive utility for MGUS as well, supporting a shared polygenic architecture.^{13,15} The estimated genetic correlation between MGUS and MM is approximately 55%, underscoring the contribution of common heritable factors.¹³ Despite these advances, the biological mechanisms linking genetic variation to disease onset remain incompletely understood.¹⁸ Recent studies suggest that dysregulation of cellular stress responses, including endoplasmic reticulum stress and oxidative stress, may contribute to plasma cell transformation.^{19–21} Additional processes implicated in this cellular reprogramming include heat shock protein chaperoning,²² aggresome formation,²³ and autophagy.²⁴ Among these, autophagy has drawn increasing attention for its complex roles in immune regulation and cell fate. Autophagy influences B-cell development and proliferation,²⁵ governs plasma cell survival,^{26,27} and can either promote or suppress tumorigenesis depending on context.^{28–30}

To test this hypothesis, we investigated 40,089 common SNPs within 234 autophagy-related genes in four European GWAS cohorts (UK Biobank, and German, Czech, and Swedish populations). The top associations were replicated in two independent datasets (Mayo/MD Anderson and IMMENSE/IBERICAT).^{16,31} We then assessed the functional consequences of prioritized SNPs using a systems-level immunogenomic approach in a large healthy donor cohort (500 Functional Genomics; 500FG) from the Human Functional Genomics Project (HFGP). Specifically, we evaluated associations between these SNPs and a broad range of immune traits, including circulating concentrations of 103 plasma and serum inflammatory proteins and counts of 91 immune cell subsets in whole blood (WB), PBMCs, and monocyte-derived macrophages (MDM). This integrative framework has previously yielded key insights into the pathogenesis of B-cell malignancies,^{32–35} solid tumors,^{36–38} immune-related disorders³⁹ and infectious conditions.⁴⁰

2 | MATERIALS AND METHODS

A workflow diagram of the study is included in Figure 1.

2.1 | Study populations (discovery cohorts)

The discovery population consisted of 243 MGUS patients and 1285 healthy controls from Germany, 288 MGUS cases and 600 controls (Czech), 461 MGUS patients and 1025 controls (Swedish) and 107 MGUS cases and 277,496 controls (UK Biobank). Detailed methodological descriptions for the German, Czech, and Swedish GWAS have been published previously.¹⁴ For these European cohorts, genotype data underwent rigorous, site-specific quality control prior to imputation using either IMPUTE2 v2.3 or the Michigan imputation server, based on the Haplotype Reference Consortium panel,⁴¹ respectively. After imputation, each site filtered the data to include only high-quality imputed variants (information score >0.8), and further quality-control checks were implemented including checks for missingness, duplicates, abnormal heterozygosity, cryptic relatedness, population outliers (evaluated by principal components analyses using Eigenstrat software), and genomic inflation ($\lambda = 1.00$).^{13,42}

The UK Biobank, a large-scale biomedical resource comprising genetic and health information from approximately 500,000 individuals aged 40 to 69 years across the United Kingdom, was analyzed independently.⁴³ MGUS cases were identified through cancer registry data using ICD-10 code D47.2 and ICD-O-3 code 9765 (Data-Fields 40011 and 40006). Controls were selected by excluding participants with any history of cancer, as recorded in cancer registries, hospital episode statistics, or self-reported data. Further exclusions concerned individuals of non-white British ancestry, sex chromosome aneuploidy, discordance between genetic and reported sex, relatedness, and other standard sample-level quality control exclusions recommended by the UK Biobank for genetic association analyses.⁴³

After quality control, a total of 107 MGUS cases and 277,496 controls remained for analysis. GWAS was conducted using REGENIE v3.2,⁴⁴ following a two-step approach. In brief, step 1 involved whole-genome ridge regression using non-imputed genotype data filtered for high quality (MAF >1%, MAC >5, genotyping rate >99%, HWE $p > 10^{-8}$, and <1% missingness), applying a leave-one-chromosome-out (LOCO) scheme. Step 2 performed variant-level association testing using logistic ridge regression, incorporating saddle-point approximation (SPA) corrections for variants with score test p -values <.01. Standard errors were derived from the effect estimates and likelihood ratio test p -values. Both steps included covariates: age (at diagnosis for cases, at recruitment for controls), sex, genotyping array, and the first 10 genetic principal components. The main demographic characteristics of discovery populations, including age, sex distribution and ancestry, are summarized in Table 1.

2.2 | Single nucleotide polymorphism selection and meta-analysis of the discovery cohorts

A total of 234 autophagy-related genes were selected based on their presence in the autophagy database (<http://autophagy.lu/index.html>; Table S1). Estimates of association with MGUS risk for all genotyped or imputed SNPs within or near these genes (5 kb up-stream and 3 kb




FIGURE 1 Flow diagram of the study.

downstream) were extracted from the four GWAS datasets and meta-analyzed using R studio v4.3.0⁴⁵ and METAL.⁴⁶ The I^2 statistic was used to assess statistical heterogeneity between the studies, and the pooled odds ratio (OR) was computed using the fixed-effect model for SNPs showing no significant heterogeneity. We obtained 40,089 SNPs, and, among them, 34,042 SNPs were present in all datasets. After the meta-analysis of the four GWAS cohorts, we selected for replication independent autophagy-related SNPs associated with MGUS risk ($n = 1303$). After excluding SNPs that showed a MAF <0.005 and a p -value $\geq .001$ in the association analysis and a heterogeneity $p \leq .05$, we ended up with 600 SNPs that included 5 independent associations signals that were selected for further replication (Table S2). Pairwise linkage disequilibrium (LD) between SNPs was assessed using the LDlinkR package (v1.1.2) interfacing the LDlink API (<https://ldlink.nci.nih.gov/>) with data from European populations of the 1000 Genomes Project. Independent SNPs were defined as those showing an LD $r^2 < 0.1$.

2.3 | Replication cohorts, genotyping and overall meta-analysis

The SNPs selected for replication in the previous step were then tested for association with MGUS risk in the Mayo Clinic/MD Anderson cohort (744 MGUS cases and 879 healthy controls) and the International Multiple Myeloma rESEarch (IMMEnSE) consortium and IBERICAT (474 MGUS cases and 1073 healthy controls).¹⁶ The Mayo Clinic/MD Anderson cohort is a case-control study comprising individuals diagnosed with MGUS and unrelated healthy controls recruited at the Mayo Clinic and The University of Texas MD Anderson Cancer Center, with cases diagnosed between 2002 and 2014, with diagnosis established according to standard International Myeloma Working Group (IMWG) criteria.¹ IMMEnSE is a retrospective case-control study that includes individuals diagnosed with MGUS, smoldering multiple myeloma, and multiple myeloma. IBERICAT is an on-going cohort study including all newly diagnosed MGUS, multiple myeloma and smoldering myeloma in four Catalan hospitals since

TABLE 1 Demographic characteristics of MGUS cases and controls across study cohorts.

Discovery cohorts ^a	MGUS cases (n)	Controls (n)	Ethnicity	Age, cases (mean ± SD)	Age, controls (mean ± SD)	Male cases (%)	Female cases (%)	Male controls (%)	Female controls (%)
Germany	243	1285	White Europeans	62.0 ± 11.0	60.0 ± 8.0	47.0	53.0	59.0	41.0
Czech Republic	288	600	White Europeans	62.0 ± 12.0	45.0 ± 13.0	51.0	49.0	48.0	52.0
Sweden (NSHDS/UFO)	461	1015	White Europeans	59.0 ± NR	56.0 ± NR	46.0	54.0	14.4	85.6
Validation cohorts	MGUS cases (n)	Controls (n)	Ethnicity	Age, cases (mean ± SD)	Age, controls (mean ± SD)	Male cases (%)	Female cases (%)	Male controls (%)	Female controls (%)
Mayo Clinic/MD Anderson	744	879	White Europeans	65.4 ± 10.8	61.2 ± 10.4	57.8	42.2	45.4	54.6
IMMEense/IBERICAT	474	1073	White Europeans	63.8 ± 12.7	50.2 ± 12.9	52.1	47.9	50.8	49.2

Abbreviation: NR, not reported.

^aIndividual-level demographic data for the UK Biobank cohort are not available due to data access restrictions. Therefore, age and sex distributions are not shown for this population. Only summary-level information provided by UK Biobank was used for association analyses.

2020. Genotyping data of selected SNPs were extracted from GWAS data. Demographic characteristics of the validation cohorts are summarized in Table 1.

All SNPs with a MAF >0.1 showed genotype frequencies in the control population similar to those found in the 1000 Genomes database (data not shown) and were in HWE. Finally, in order to analyze the overall impact of selected variants on MGUS risk, we performed an overall meta-analysis of the six independent studies using METAL.⁴⁶ As before, the I^2 statistic was used to assess heterogeneity among the studies, and the pooled odds ratio (OR) was computed using the fixed-effect model for SNPs showing no significant heterogeneity. Multiple testing significance threshold was set to 3.84×10^{-5} (0.05/1303 independent SNPs).

2.4 | Association of the autophagy-related variants with host immune responses

The five autophagy-related SNPs showing the most significant associations with MGUS risk were tested for their association with cytokine expression quantitative trait loci (cQTL) data after in vitro stimulation experiments. We also analyzed whether the SNPs were associated with absolute numbers of 91 blood-derived cell populations and 103 serum and plasmatic immunological proteins quantified in the approximately 550 volunteers of the 500 Functional Genomics (500FG) cohort from the Human Functional Genomics Project (<http://www.humanfunctionalgenomics.org/site/>).

cQTL data included cytokine levels (IFN γ , IL1 β , IL6, TNF α , IL17, and IL22) after the stimulation of peripheral blood mononuclear cells (PBMCs), monocyte-derived macrophages (MDM), or whole blood from 408 healthy subjects with LPS (1 or 100 ng/mL; Sigma Aldrich, St. Louis, MO, USA), PHA (10 μ g/mL, Sigma, St. Louis, MO, USA), Pam3Cys (10 μ g/mL, EMC microcollections, Tübingen, Germany), CpG (100 ng/mL, InvivoGen, San Diego, CA, USA), *Borrelia burgdorferi*

(ATCC 35210), *Escherichia coli* (ATCC 25922), and *Porphyromonas gingivalis* (ATCC 33277) for 24 or 48 h at 37°C and 5% CO₂. After log transformation, linear regression analyses adjusted for age and sex were used to determine the association of the selected SNPs with cQTL data. Details on PBMC isolation, macrophage differentiation, and whole blood stimulation assays have been reported elsewhere.⁴⁷

To examine the impact of autophagy SNPs on cell-level variation, 91 blood-derived cell populations were measured by 10-color flow cytometry (Navios flow cytometer, Beckman Coulter, Miami, FL, USA) after blood sampling (2–3 h), and cell count analysis was performed using Kaluza software (Beckman Coulter, v.1.3) (Table S3). To reduce inter-experimental noise and increase statistical power, cell count analysis was performed by calculating parental and grandparental percentages, which were defined as the percentage of a certain cell type within the subpopulation of the cells from which it was isolated.⁴⁷ Detailed laboratory protocols for cell isolation, reagents, gating, and flow cytometry analysis have been reported elsewhere.⁴⁸

Serum and plasma samples from the HFGP study were also subjected to targeted proteomic analysis. Circulating proteins were measured using the commercial Olink[®] Inflammation panel (Olink, Sweden) that resulted in the measurement of 103 different biomarkers (Table S4). Protein levels were expressed on a log₂-scale as normalized protein expression values and normalized using bridging samples to correct for batch variation.

All analyses were performed using R software (<http://www.r-project.org/>) through custom scripts that implemented linear regression models using the `lm()` function from the stats package. Gene expression data were log₁₀-transformed, and models were adjusted for age and sex as covariates. To account for multiple comparisons, we used Bonferroni corrected significance thresholds of 3.33×10^{-4} (0.05/5 SNPs/6 cytokines/5 stimulus), 1.10×10^{-4} (0.05/5 SNPs/91 cell-derived populations), and 9.71×10^{-5} (0.05/5 SNPs/103 proteins) for the cQTL, cell variability, and proteomic analyses, respectively.

2.5 | In silico functional analysis

Haploreg (<http://www.broadinstitute.org/mammals/haploreg/haploreg.php>)⁴⁹ and ENCODE annotation data (<https://genome.ucsc.edu/ENCODE>)⁵⁰ were also used to predict the functional role of the most interesting autophagy SNPs. We also analyzed whether selected SNPs could be expression quantitative trait loci (eQTL) for different cell types and tissues using data from public eQTL browsers such as GTEx portal (<https://gtexportal.org/home/>),⁵¹ Blood eQTL browser (<https://genenetwork.nl/bloodeqtlbrowser/>).⁵²

3 | RESULTS

3.1 | Association of autophagy-related polymorphisms with the risk of developing MGUS

This study included four European populations, comprising a total of 1099 MGUS patients and 280,406 healthy controls from the German, Czech, Swedish, and UKBB GWAS datasets used as discovery cohorts.

In the discovery phase, the meta-analysis identified several autophagy-related variants associated with MGUS risk. The strongest association was observed for *ULK4*_{rs6599175} ($p = 2.04 \times 10^{-6}$). Four additional SNPs also showed relatively strong associations: *CDKN2A*_{rs2811710} ($p = 3.40 \times 10^{-4}$), *ATG10*_{rs1109846} ($p = 7.11 \times 10^{-4}$), *ITPR1*_{rs11716177} ($p = 6.40 \times 10^{-4}$), and *EIF4G1*_{rs56148883} ($p = 5.40 \times 10^{-4}$).

We then selected independent variants ($r^2 < 0.1$) with MAF > 0.005 and $p \leq .001$ for replication in the Mayo Clinic/MD Anderson and IMMENSE/IBERICAT cohorts. Replication in these two large, independent cohorts was critical, as it enabled us to demonstrate for the first time a genome-wide significant association between the *ULK4* locus and MGUS risk ($p < 5 \times 10^{-8}$; Table 2). The combined meta-analysis of all six populations confirmed the association of the *ULK4* locus with MGUS risk ($p = 3.35 \times 10^{-8}$). In addition, although not statistically significant after correction for multiple testing (p -Bonferroni = 3.84×10^{-5}), we observed a suggestive association between the *CDKN2A*_{rs2811710} variant and MGUS risk ($p = 2.17 \times 10^{-4}$).

3.2 | Association of autophagy-related SNPs with gene expression and host immune responses

Data from the GTEx portal provided functional relevance of *ULK4*_{rs6599175} by showing that it strongly associates with *ULK4* mRNA expression in whole blood ($p = 2.55 \times 10^{-81}$; Figure S1).

To investigate the potential biological impact of the identified variants, we explored whether the *ULK4* polymorphism could modulate host immune responses, circulating immunological proteins, and blood-derived immune cell populations, using data from the 500FG cohort from the HFPG. Although the association of *CDKN2A*_{rs2811710} with MGUS risk was modest and did not remain significant after correction for multiple testing, we included this variant in the functional

TABLE 2 Association analysis of autophagy-related SNPs representing susceptibility regions for MGUS.

SNP	Gene	German GWAS		Czech GWAS		Swedish GWAS		UKBB GWAS		Discovery meta-analysis		Mayo/MD Anderson cohort		IMMENSE/IBERICAT cohort		Overall meta-analysis	
		n	P	n	P	n	P	n	P	n	P	n	P	n	P	n	P
rs6599175	ULK4	1528	1.52 (1.20–1.92)	888	1.49 (1.16–1.92)	1486	1.21 (0.99–1.50)	277,603	6.71×10^{-2}	281,505	2.04×10^{-6}	1623	1.28 (1.05–1.57)	1547	1.18 (0.96–1.46)	284,675	3.35×10^{-8}
rs2811710	CDKN2A	1285	1.00 (0.81–1.25)			1025	1.29 (1.07–1.55)	277,496	7.89×10^{-3}	(1099 MGUS and 280,406 healthy controls)	1.23 (1.10–1.37)	744 MGUS and 879 healthy controls	1.45 (1.14–1.86)	(474 MGUS and 1073 healthy controls)	1.46 (1.07–1.98)	(2317 MGUS and 282,358 healthy controls)	2.17×10^{-4}
rs1109846	ATG10		1.21 (0.94–1.56)		1.35 (1.03–1.78)		1.22 (1.01–1.48)		4.38×10^{-2}		1.24 (1.10–1.41)		0.92 (0.67–1.02)		0.74 (0.56–1.19)		1.05
rs11716177	ITPR1		1.13 (0.79–1.62)		1.40 (0.97–2.03)		1.42 (1.03–1.97)		3.34×10^{-2}		1.39 (1.15–1.68)		0.86 (0.63–1.17)		0.93 (0.60–1.43)		0.43
rs56148883	EIF4G1		1.39 (0.99–1.97)		1.19 (0.80–1.77)		1.34 (1.00–1.82)		5.36×10^{-2}		1.38 (1.15–1.66)		0.92 (0.68–1.24)		1.51 (1.09–2.09)		0.169

Note: $p < .05$ in bold.
Abbreviations: A1, effect allele; P, p-value; SNP, single nucleotide polymorphism.
^ars2811710 is in LD with rs7036656 ($D' = 0.9407$ and $r^2 = 0.6325$).

analyses due to its well-established roles in the autophagy pathway and its prior role seen in MM.

Interestingly, we found that carriers of the *ULK4*_{rs6599175C} allele showed reduced counts of memory B cell subsets (IgM+CD38+CD27+ and IgD+IgM+CD27+; $p = .0038$ and $p = .0056$, respectively; Figure 2A,B) and natural effector B cells (CD24+CD38+IgD+IgM+ cells; $p = .0060$; Figure 2C), suggesting that *ULK4* may influence early B-cell differentiation in plasma cell dyscrasia. On the other hand, we failed to find positive associations between the *CDKN2A*_{rs2811710} SNP and host immune parameters, which suggested that the *CDKN2A* locus does not modulate MGUS risk through the regulation of host immune responses. Additional functional studies are now warranted to decipher the mechanistic process by which this locus is affecting MGUS risk.

4 | DISCUSSION

This study fills a critical gap in the field by presenting the first systematic evaluation of autophagy-related genetic variation in MGUS.

Through a large-scale meta-analysis across five European cohorts and one North American cohort, we identified, for the first time, a genome-wide significant association between the *ULK4* gene and MGUS susceptibility, marking a key advance in our understanding of early-stage plasma cell dyscrasias.

The rs6599175C allele in *ULK4* was associated with a 29% increased risk of MGUS, consistent with previously reported effect sizes in MM¹⁴ and AL amyloidosis⁵³ (26% and 30%, respectively). This convergence suggests that *ULK4* may play a broader role in plasma cell dyscrasias, although its specific involvement in disease progression toward MM remains unclear. Previous studies examined this locus in broader or combined disease contexts (e.g., pooled MGUS/MM cohorts)^{14,15,54} or through polygenic risk score approaches,¹³ which may have lacked the resolution to detect locus-specific associations. Our findings provide genome-wide significant evidence supporting a potential role for *ULK4* in MGUS susceptibility and highlight the value of studying precursor conditions independently.

The *ULK4* gene is located on chromosome 3p22.1 and encodes for a member of the unc-51-like serine/threonine kinase (STK) family,




FIGURE 2 Association of the *ULK4*_{rs6599175} SNP and numbers of different B cell subtypes. (A) Association between the *ULK4*_{rs6599175} SNP and the number of class non-switched memory IgM+CD38+CD27+ cells; (B) Association between the *ULK4*_{rs6599175} SNP and the number of IgD+IgM+CD27+ memory B cells; (C) Association between the *ULK4*_{rs6599175} SNP and the number of natural effector CD24+CD38+IgD+IgM+ cells.

which is involved in various biological processes, including cytoskeletal remodeling and cell motility through regulation of mTOR-mediated autophagy. Furthermore, the identified variant has been associated with increased risk of hypertension,⁵⁵ cardiovascular disorders,⁵⁶ and other conditions.⁵⁷ According to data from the GTEx portal, *ULK4*_{rs6599175} strongly associates with *ULK4* mRNA expression in whole blood ($p = 2.55 \times 10^{-81}$) and multiple tissues,⁵⁸ suggesting that this variant may directly influence *ULK4* protein concentrations. Additionally, our group has previously reported that the *ULK4*_{rs6599175C} allele associates with serum concentrations of vitamin D3 in healthy donors,^{59–61} further supporting a role for *ULK4* in modulating processes such as cell differentiation and proliferation, angiogenesis, immune responses and apoptosis, in both unaffected and malignant tissues. However, in our previous study, we did not observe an association between this variant and autophagic flux, suggesting that its effects may be mediated through alternative or indirect pathways. In support of this notion, we found suggestive associations of the *ULK4*_{rs6599175C} allele with reduced counts of IgM+CD38+CD27+ and IgD+IgM+CD27+ cells and natural effector CD24+CD38+IgD+IgM+ B cells, suggesting that the *ULK4* gene may influence B-cell development and immune homeostasis relevant to MGUS initiation.

Beyond *ULK4*, we also observed that the *CDKN2A*_{rs2811710} SNP showed a suggestive association with MGUS risk. Although this association did not remain statistically significant after correction for multiple testing, this may reflect limited statistical power due to modest effect sizes and the low prevalence of MGUS, as well as potential locus heterogeneity or context-dependent regulatory effects that are not fully captured in standard case-control GWAS. Nevertheless, it is reasonable to hypothesize that this variant may influence susceptibility to MGUS, given that *CDKN2A* has previously been implicated in multiple myeloma risk in family-based studies.⁶¹ A previous study similarly failed to detect a statistically significant association after multiple testing correction but acknowledged that the lack of significance might have been due to limited statistical power.¹³

The *CDKN2A*_{rs2811710C} allele was not associated with immunological parameters in the 500FG cohort; however, multiple lines of evidence support its functional effect. According to Haploreg data, the *CDKN2A*_{rs2811710C} variant associates with *CDKN2A* and *STK16* mRNA expression levels in peripheral blood monocytes ($p = 1.24 \times 10^{-15}$ and $p = 5.48 \times 10^{-6}$, respectively)⁵² and resides in histone-marked regions of regulatory chromatin across several blood cell types, including effect memory T cells, primary B cells and naïve and memory CD4+ and CD8+ T cells. In addition, this SNP alters transcription binding sites for key transcription factors, such as p300, Foxd3, HDAC2, HNF1, and OTX that modulate hematopoietic stem cell differentiation and proliferation^{63–65} and mature B cell proliferation.^{66–69} Overall, these findings suggest a functional role of this variant in modulating the risk of MGUS.

The *CDKN2A* gene, localized on chromosome 9p21.3, encodes a cyclin-dependent kinase inhibitor 2A, a well-established tumor suppressor protein.^{70,71} This protein is involved in p53 stabilization, cell cycle arrest, inhibition of cell proliferation, induction of cellular senescence, and regulation of DNA methylation.^{72–75} Recent evidence has

also highlighted a role for *CDKN2A* in autophagy regulation and cellular senescence. Specifically, a conserved domain within exon 2 is required for ARF-mediated autophagy induction, a function that is disrupted by tumor-associated mutations.⁷⁶ Although it remains unclear whether the *CDKN2A* locus exerts its effects during the pre-tumoral stages or later during tumor progression, our findings support the role of this gene in determining MGUS predisposition, suggesting its involvement at the earliest stages of plasma cell neoplasia. Furthermore, previous studies have reported that germline mutations in *CDKN2A* are associated with overall survival in MM patients,⁷⁷ supporting the hypothesis that this locus is central in modulating susceptibility, and/or progression in plasma cell disorders such as MGUS and MM. While additional evidence is needed, *CDKN2A* could potentially serve as a biomarker for identifying individuals at increased risk of developing MGUS or for stratifying MGUS patients according to their likelihood of progression to MM. It may also represent a candidate for therapeutic exploration in the early stages of plasma cell dyscrasias.

This study has several strengths and limitations. It leverages the largest MGUS genetic dataset to date, comprising 284,675 individuals of European ancestry (2317 MGUS cases and 282,358 healthy controls), and evaluates inherited variation across 234 autophagy-related genes. The integration with immune phenotyping data from the 500FG cohort allowed us to explore functional consequences of the most relevant variants on immune cell populations and circulating inflammatory proteins. However, MGUS remains an asymptomatic condition, limiting the number of available cases and our ability to detect associations with rare variants. Although most cohorts were not systematically screened for subclinical MGUS, the majority of MGUS cases included in this study were clinically diagnosed by hematologists according to established diagnostic criteria. The UK Biobank cohort represents the exception, where MGUS cases were ascertained using registry-based ICD codes, which may be subject to misclassification, coding errors, and lack of confirmation by standardized hematological diagnostic criteria, and may therefore not fully capture clinically validated MGUS cases. Controls consisted of elderly individuals without a known clinical diagnosis of plasma cell dyscrasia. Any potential inclusion of undiagnosed MGUS among controls would be expected to bias effect estimates toward the null, rendering our observed associations conservative. The European-only ancestry of participants may also restrict the applicability of these findings to other populations. To address these challenges, future research should focus on building large, ethnically diverse, and longitudinal MGUS cohorts to improve statistical power and generalizability.

5 | CONCLUSIONS

This study demonstrates that genetic variation in the autophagy-related gene *ULK4* is associated with increased risk of MGUS. Our functional data indicated that the *ULK4*_{rs1109846} variant may contribute to MGUS susceptibility by modulating *ULK4* mRNA expression levels and abundance of specific B cell subsets. Together with our previous findings showing that this SNP influences circulating

concentrations of vitamin D3, these results suggest a central role for *ULK4* in regulating vitamin D3-mediated B-cell immune responses. In addition, based on both genetic and functional analyses, we identified for the first time a SNP within the *CDKN2A* gene as a potential susceptibility marker for MGUS. The effect of the *CDKN2A* variant on MGUS risk might be mediated by its effect on mRNA transcription in monocytes and transcription factors possibly affecting cell differentiation.

AUTHOR CONTRIBUTIONS

José Manuel Sánchez-Maldonado: Writing – original draft; investigation; data curation; formal analysis. **Angelica Macaudo:** Writing – review and editing; investigation. **Antonio José Cabrera-Serrano:** Investigation; data curation; formal analysis; writing – original draft. **Hauke Thomsen:** Writing – review and editing; resources; data curation. **Murat Güler:** Writing – review and editing; data curation. **Rob Ter Horst:** Writing – review and editing; resources; data curation; investigation. **Bethany van Guelpen:** Writing – review and editing; resources. **Pavel Vodicka:** Writing – review and editing; resources. **Stefano Landi:** Writing – review and editing; resources. **Subhayan Chattopadhyay:** Writing – review and editing; resources. **Pelin Ünal:** Writing – review and editing; resources. **Lucía Ruiz-Durán:** Resources; writing – review and editing. **Delphine Casabonne:** Writing – review and editing; resources. **Hartmut Goldschmidt:** Writing – review and editing; resources. **Istemi Serin:** Writing – review and editing; resources. **María Carretero-Fernández:** Writing – review and editing; resources. **Elena Cabezudo:** Writing – review and editing; resources. **Fernando Reyes Zurita:** Writing – review and editing; resources. **Aaron D. Norman:** Writing – review and editing; resources. **Ramón García-Sanz:** Writing – review and editing; resources. **Gabriele Capurso:** Writing – review and editing; resources. **Per Hoffmann:** Writing – review and editing; resources. **Ulrika Pettersson-Kymmer:** Writing – review and editing; resources. **Francisco Jiménez-Romera:** Writing – review and editing; resources. **S. Vincent Rajkumar:** Writing – review and editing; resources. **Niels Weinhold:** Writing – review and editing; resources. **Ludmila Vodickova:** Writing – review and editing; resources. **Christian Langer:** Writing – review and editing; resources. **Angelika Stein:** Writing – review and editing; resources; methodology. **Abdulkadir Karismaz:** Writing – review and editing; resources. **Victor Moreno:** Writing – review and editing; resources. **Markus M. Nöthen:** Writing – review and editing; resources. **Karl-Heinz Jöckel:** Writing – review and editing; resources. **Francesca Tavano:** Writing – review and editing; resources. **Joaquín Martínez López:** Writing – review and editing; resources. **Shaji K. Kumar:** Writing – review and editing; resources. **Juan Francisco Gutiérrez-Bautista:** Writing – review and editing; resources. **Daniela Basso:** Writing – review and editing; resources. **Florentin Späth:** Writing – review and editing; resources. **Yolanda Benavente:** Writing – review and editing; resources. **Michelle A. T. Hildebrandt:** Writing – review and editing; resources. **Börge Schmidt:** Writing – review and editing; resources. **Tereza Sevcikova:** Writing – review and editing; resources. **Rui Manuel Vieira Reis:** Writing – review and editing; resources. **Yang Li:** Writing – review and editing; resources; investigation; data curation. **Miguel Ángel López-Nevot:** Writing – review and editing; resources.

Mihai G. Netea: Writing – review and editing; resources; investigation; data curation. **Daniele Campa:** Resources; writing – review and editing. **Alyssa Clay-Gilmour:** Writing – review and editing; resources. **Susan Slager:** Writing – review and editing; resources. **Kari Hemminki:** Writing – review and editing; resources. **Celine Vachon:** Resources; writing – review and editing. **Asta Försti:** Conceptualization; writing – review and editing; data curation. **Federico Canzian:** Conceptualization; writing – review and editing; data curation. **Juan Sainz:** Conceptualization; writing – original draft; funding acquisition; supervision; resources; project administration; data curation; formal analysis.

AFFILIATIONS

- ¹Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain
- ²Instituto de Investigación Biosanitaria IBs.Granada, Granada, Spain
- ³Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
- ⁴MSB Medical School Berlin, Berlin, Germany
- ⁵Medical Faculty, Heidelberg University, Heidelberg, Germany
- ⁶Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
- ⁷CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- ⁸Department of Diagnostics and Intervention, Oncology Unit, Umeå University, Umeå, Sweden
- ⁹Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden
- ¹⁰Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic
- ¹¹Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- ¹²Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic
- ¹³Department of Biology, University of Pisa, Pisa, Italy
- ¹⁴Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
- ¹⁵Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, l'Hospitalet de Llobregat, Spain
- ¹⁶Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- ¹⁷Heidelberg University, Heidelberg, Germany
- ¹⁸Istanbul Basaksehir Cam and Sakura City Hospital, Department of Hematology and Adult Bone Marrow Transplantation Unit, University of Health Sciences, Istanbul, Turkey
- ¹⁹Hematolog, Catalan Institute of Oncology, l'Hospitalet de Llobregat, Spain
- ²⁰Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain
- ²¹Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain

²²Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA

²³CIBERONC, Institute of Cancer and Hematological Diseases, Gregorio Maraón General, Madrid, Spain

²⁴Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy

²⁵“Vita-Salute” San Raffaele University, Milan, Italy

²⁶Institute of Human Genetics, University of Bonn, Bonn, Germany

²⁷Department of Biomedicine, University of Basel, Basel, Switzerland

²⁸Clinical Pharmacology, Department of Pharmacology and Clinical Neuroscience, Umea University, Umea, Sweden

²⁹Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

³⁰Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

³¹Kempton Clinic, Kempton, Germany

³²Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey

³³Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain

³⁴Colorectal Cancer Group, ONCOBELL, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

³⁵Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), Madrid, Spain

³⁶Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain

³⁷Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

³⁸Division of Gastroenterology and Endoscopy, Fondazione IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo (FG), Italy

³⁹Hospital Universitario 12 de Octubre, University Complutense, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain

⁴⁰Servicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, Granada, Spain

⁴¹Departamento de Bioquímica, Biología Molecular e Inmunología III, University of Granada, Granada, Spain

⁴²Department of Medicine, University of Padova Medicina di Laboratorio, Padova, Italy

⁴³Department of Diagnostics and Intervention, Cancer Center, Hematology, Umeå University, Umeå, Sweden

⁴⁴Department of Public Health, Mental Health and Maternal and Child Health Nursing, Faculty of Nursing, University of Barcelona, Barcelona, Spain

⁴⁵Department of Lymphoma—Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

⁴⁶Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic

⁴⁷Department of Hematooncology, Faculty of Medicine University of Ostrava, Ostrava, Czech Republic

⁴⁸Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal and ICVS/3B's—PT Government Associate Laboratory, Braga/Guimarães, Portugal

⁴⁹Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil

⁵⁰Centre for Individualised Infection Medicine (CiIM) & TWINCORE, Joint Ventures between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany

⁵¹Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany

⁵²Department of Biostatistics and Epidemiology, Arnold School of Public Health, University of South Carolina, Greenville, South Carolina, USA

⁵³Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Rochester, Minnesota, USA

⁵⁴Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

⁵⁵Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic

⁵⁶Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

⁵⁷Hopp Children's Cancer Center (KITZ), Heidelberg, Germany

ACKNOWLEDGMENTS

We are grateful to the UK Biobank study and its participants. This research has been conducted using the UK Biobank resource under Application 66591. We would also like to thank all the patients who participated in the IBERICAT study, as well as the IBERICAT study collaborators: Lina Abenoza, Laura Abril, Laia Alemany, Angelica Aranda, Iago Arribas, Cristina Baca, Yolanda Benavente, Carla Bermúdez, Anna Bosch, Ainhoa Botella, Gabriela Bustamante, Elena Cabezudo, Vanessa Camón, Itziar Carro, Delphine Casabonne, Victoria Clapés, Alessandra Comai, Abel Domingo, Cristina Espi, Ana Esteban, Yolanda Florencia Melgarejo, Enrique Gamundi, Ana Garzo Moreno, Eduardo González Gómez, Yolanda González Montes, Sara Hermosa, Saray Hosa, Gladys Ibarra, María Izquierdo Montagut, María Francisca Llopis, Cristina López, Laia Martí, Albert Oriol Rocafiguera, Natividad Paton, Miguel Ángel Pavón, Teresa Quiñones, Miriam Ratia, Sheila Sánchez, Miriam Sanz, Iván Sánchez Rodríguez, María Alicia Senin Magan, Anna Sureda, and Marleny Vergara. This work was supported by the Instituto de Salud Carlos III (Madrid, Spain; DTS23/00030, PI17/02256 and PI20/01845), and from the Consejería de Salud y Familia de la Junta de Andalucía (PY20/01282). In addition, this work was funded by the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), action Genrisk. The funders had no role in the writing of the manuscript, or in the decision to publish the reviewed material. Funding for open access charge: Universidad de Granada/CBUA. This research included biospecimens from the Department of Epidemiology's Population Sciences Laboratory that is supported, in part, by The University of Texas MD Anderson Cancer Center Permanent Health Funds, and by a philanthropic gift from APA Corporation.

CONFLICT OF INTEREST STATEMENT

Hartmut Goldschmidt reports research funding and/or provision of investigational medicinal products from BMS/Celgene, Dietmar Hopp Foundation, Janssen, and Sanofi. He has received research support from Amgen, BMS, Celgene, GlycoMimetics Inc., GlaxoSmithKline (GSK), Heidelberg Pharma, Hoffmann-La Roche, Janssen Research and Development, Millennium, Novartis, Pfizer, Oncoceptides, and Sanofi. He has served on advisory boards for BMS, Janssen, Sanofi, and GSK. He has received honoraria from Amgen, BMS, GSK, Janssen, Sanofi, Pfizer, and Oncoceptides and travel support from Amgen, BMS, GSK, Janssen, Sanofi, Pfizer, and Oncoceptides. All other authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

The UK Biobank is an open access resource and bona fide researchers can apply to use the UK Biobank dataset by registering and applying at <https://www.ukbiobank.ac.uk/use-our-data/apply-for-access/>. The summary statistics of the UK Biobank MGUS GWAS are available in Zenodo with: <https://zenodo.org/records/10533713>. Functional data used in this project have been meticulously catalogued and archived in the BBMRI-NL data infrastructure (<https://hfgp.bbmri.nl/>) using the MOLGENIS open-source platform for scientific data.⁷⁸ The genotype data used in the present study and further information are available by the corresponding authors upon reasonable request.

ETHICS STATEMENT

Each participant in the German, Czech, and Swedish GWAS, as well as in the UK Biobank GWAS and the Mayo/MD Anderson and IMMENSE/IBERICAT studies, obtained approval from the respective institutional review board (IRB) and IRB certification permitting data sharing in accordance with the NIH Policy for Sharing of Data Obtained in NIH-Supported or NIH-Conducted Genome-Wide Association Studies. The IMMENSE study protocol was approved by the Ethics Commission of the Medical Faculty of the University of Heidelberg (S-565/2015; last update on April 3, 2017) and the IBERICAT research protocol was approved by the Center Ethics Committee of Hospital de Bellvitge (Ref PR248/19). In accordance with the Declaration of Helsinki, written informed consent was obtained from each participant. The HFGP study was also approved by the Arnhem-Nijmegen Ethical Committee (no. 42561.091.12), and biological specimens were collected only after informed consent had been obtained.

ORCID

Bethany van Guelpen  <https://orcid.org/0000-0002-9692-101X>
Stefano Landi  <https://orcid.org/0000-0001-8364-6357>
Delphine Casabonne  <https://orcid.org/0000-0002-7874-3707>
Victor Moreno  <https://orcid.org/0000-0002-2818-5487>
Francesca Tavano  <https://orcid.org/0000-0002-8831-7349>
Michelle A. T. Hildebrandt  <https://orcid.org/0000-0001-6769-6872>
Börge Schmidt  <https://orcid.org/0000-0001-6948-7273>
Rui Manuel Vieira Reis  <https://orcid.org/0000-0002-9639-7940>

Daniele Campa  <https://orcid.org/0000-0003-3220-9944>

Asta Försti  <https://orcid.org/0000-0002-9857-4728>

Federico Canzian  <https://orcid.org/0000-0002-4261-4583>

Juan Sainz  <https://orcid.org/0000-0002-9355-2423>

REFERENCES

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15:e538-e548. doi:[10.1016/S1470-2045\(14\)70442-5](https://doi.org/10.1016/S1470-2045(14)70442-5)
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2006;354:1362-1369. doi:[10.1056/NEJMoa054494](https://doi.org/10.1056/NEJMoa054494)
3. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. *Nat Rev Cancer*. 2017;17:543-556. doi:[10.1038/nrc.2017.63](https://doi.org/10.1038/nrc.2017.63)
4. Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV. Monoclonal Gammopathy of undetermined significance and smoldering multiple myeloma. *Hematol Oncol Clin North Am*. 2014;28:775-790. doi:[10.1016/j.hoc.2014.06.005](https://doi.org/10.1016/j.hoc.2014.06.005)
5. Go RS, Vincent Rajkumar S. How I manage monoclonal gammopathy of undetermined significance. *Blood*. 2018;131:163-173. doi:[10.1182/blood-2017-09-807560](https://doi.org/10.1182/blood-2017-09-807560)
6. McMaster ML, Caporaso N. Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. *Br J Haematol*. 2007;139:663-671. doi:[10.1111/j.1365-2141.2007.06845.x](https://doi.org/10.1111/j.1365-2141.2007.06845.x)
7. Viera S, Ludek P, Zdeněk A, et al. Monoklonální gamapatie nejasného významu (MGUS). *Klin Onkol*. 2018;31:270-276. Accessed February 21, 2025. <https://pubmed.ncbi.nlm.nih.gov/30541309/>
8. Mateos MV, Landgren O. MGUS and smoldering multiple myeloma: diagnosis and epidemiology. *Cancer Treat Res*. 2016;169:3-12. doi:[10.1007/978-3-319-40320-5_1](https://doi.org/10.1007/978-3-319-40320-5_1)
9. Castaneda-Avila MA, Ulbricht CM, Epstein MM. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. *Ann Hematol*. 2021;100:855-863. doi:[10.1007/s00277-021-04400-7](https://doi.org/10.1007/s00277-021-04400-7)
10. Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. *Am J Hematol*. 1996;52:217-220. doi:[10.1002/\(SICI\)1096-8652\(199607\)52:33.0.CO;2-C](https://doi.org/10.1002/(SICI)1096-8652(199607)52:33.0.CO;2-C)
11. Verma KP, Steuer R, Edwards CV. Geographic prevalence patterns and modifiable risk factors for monoclonal gammopathy of undetermined significance. *Hema*. 2023;4:331-349. doi:[10.3390/hemato4040027](https://doi.org/10.3390/hemato4040027)
12. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. *J Clin Invest*. 2012;122:3456-3463. doi:[10.1172/JCI61188](https://doi.org/10.1172/JCI61188)
13. Clay-Gilmour AI, Hildebrandt MAT, Brown EE, et al. Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. *Blood Adv*. 2020;4:2789-2797. doi:[10.1182/bloodadvances.2020001435](https://doi.org/10.1182/bloodadvances.2020001435)
14. Thomsen H, Chattopadhyay S, Weinhold N, et al. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. *Leukemia*. 2019;33:1817-1821. doi:[10.1038/s41375-019-0396-x](https://doi.org/10.1038/s41375-019-0396-x)
15. Weinhold N, Johnson DC, Rawstron AC, et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. *Blood*. 2014;123:2513-2517. doi:[10.1182/blood-2013-10-532283](https://doi.org/10.1182/blood-2013-10-532283)
16. Clay-Gilmour A, Chattopadhyay S, Hildebrandt MAT, et al. Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. *Blood Cancer J*. 2022;12:60. doi:[10.1038/s41408-022-00658-w](https://doi.org/10.1038/s41408-022-00658-w)
17. Giaccherini M, Clay-Gilmour AI, Liotti R, et al. Genetically determined telomere length in monoclonal gammopathy of undetermined

- significance, multiple myeloma risk and outcome. *Blood Cancer J*. 2024;14:200. doi:[10.1038/s41408-024-01181-w](https://doi.org/10.1038/s41408-024-01181-w)
18. van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of pre-malignant cells. *Cancer Res*. 2018;78:2449-2456. doi:[10.1158/0008-5472.CAN-17-3115](https://doi.org/10.1158/0008-5472.CAN-17-3115)
 19. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated dysregulation of Ca²⁺ is a critical determinant of velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines. *Cancer Res*. 2005;65:3828-3836. doi:[10.1158/0008-5472.CAN-04-3684](https://doi.org/10.1158/0008-5472.CAN-04-3684)
 20. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. *Proc Natl Acad Sci U S A*. 2003;100:9946-9951. doi:[10.1073/pnas.1334037100](https://doi.org/10.1073/pnas.1334037100)
 21. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. *Blood*. 2006;107:4907-4916. doi:[10.1182/blood-2005-08-3531](https://doi.org/10.1182/blood-2005-08-3531)
 22. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. *Blood*. 2006;107:1092-1100. doi:[10.1182/blood-2005-03-1158](https://doi.org/10.1182/blood-2005-03-1158)
 23. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and α -tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. *Blood*. 2006;108:3441-3449. doi:[10.1182/blood-2006-04-016055](https://doi.org/10.1182/blood-2006-04-016055)
 24. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. *Mol Cancer Ther*. 2009;8:1974-1984. doi:[10.1158/1535-7163.MCT-08-1177](https://doi.org/10.1158/1535-7163.MCT-08-1177)
 25. Arsov I, Adebayo A, Kucerova-Levisohn M, et al. A role for autophagic protein Beclin 1 early in lymphocyte development. *J Immunol*. 2011;186:2201-2209. doi:[10.4049/jimmunol.1002223](https://doi.org/10.4049/jimmunol.1002223)
 26. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. *Nat Rev Mol Cell Biol*. 2008;9:1004-1010. doi:[10.1038/nrm2529](https://doi.org/10.1038/nrm2529)
 27. Shimizu S, Kanaseki T, Mizushima N, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. *Nat Cell Biol*. 2004;6:1221-1228. doi:[10.1038/ncb1192](https://doi.org/10.1038/ncb1192)
 28. Schwarten M, Mohrlüder J, Ma P, et al. Nix directly binds to GABARAP: a possible crosstalk between apoptosis and autophagy. *Autophagy*. 2009;5:690-698. doi:[10.4161/auto.5.5.8494](https://doi.org/10.4161/auto.5.5.8494)
 29. Yu L, Alva A, Su H, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. *Science*. 1979;200(304):1500-1502. doi:[10.1126/science.1096645](https://doi.org/10.1126/science.1096645)
 30. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. *Immunity*. 2013;39:211-227. doi:[10.1016/j.immuni.2013.07.017](https://doi.org/10.1016/j.immuni.2013.07.017)
 31. Martino A, Campa D, Jamrozik K, et al. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. *Br J Haematol*. 2012;158:805-809. doi:[10.1111/j.1365-2141.2012.09244.x](https://doi.org/10.1111/j.1365-2141.2012.09244.x)
 32. Sánchez-Maldonado JM, Cabrera-Serrano AJ, Chattopadhyay S, et al. GWAS-identified variants for obesity do not influence the risk of developing multiple myeloma: a population-based study and meta-analysis. *Int J Mol Sci*. 2023;24:6029. doi:[10.3390/ijms24076029](https://doi.org/10.3390/ijms24076029)
 33. Clavero E, Sanchez-Maldonado JM, Macaudo A, et al. Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma: a meta-analysis of three large cohorts and functional characterization. *Int J Mol Sci*. 2023;24:8500. doi:[10.3390/ijms24108500](https://doi.org/10.3390/ijms24108500)
 34. Macaudo A, Briem K, Clay-Gilmour A, et al. Identification of novel genetic loci for risk of multiple myeloma by functional annotation. *Leukemia*. 2023;37:2326-2329. doi:[10.1038/s41375-023-02022-8](https://doi.org/10.1038/s41375-023-02022-8)
 35. Castro I, Sampaio-Marques B, Areias AC, et al. Functional genetic variants in atg10 are associated with acute myeloid leukemia. *Cancers (Basel)*. 2021;13:1-16. doi:[10.3390/cancers13061344](https://doi.org/10.3390/cancers13061344)
 36. Sainz J, García-verdejo FJ, Martínez-bueno M, et al. Polymorphisms within autophagy-related genes influence the risk of developing colorectal cancer: a meta-analysis of four large cohorts. *Cancers (Basel)*. 2021;13:1-15. doi:[10.3390/cancers13061258](https://doi.org/10.3390/cancers13061258)
 37. Sánchez-Maldonado JM, Collado R, Cabrera-Serrano AJ, et al. Type 2 diabetes-related variants influence the risk of developing prostate cancer: a population-based case-control study and meta-analysis. *Cancers (Basel)*. 2022;14:2376. doi:[10.3390/cancers14102376](https://doi.org/10.3390/cancers14102376)
 38. Gálvez-Montosa F, Peduzzi G, Sanchez-Maldonado JM, et al. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: a meta-analysis of three large European cohorts and functional characterization. *Int J Cancer*. 2025;156:339-352. doi:[10.1002/ijc.35196](https://doi.org/10.1002/ijc.35196)
 39. Sánchez-Maldonado JM, Cáliz R, López-Nevot MÁ, et al. Validation of GWAS-identified variants for anti-TNF drug response in rheumatoid arthritis: a meta-analysis of two large cohorts. *Front Immunol*. 2021;12:672255. doi:[10.3389/fimmu.2021.672255](https://doi.org/10.3389/fimmu.2021.672255)
 40. Sánchez-Maldonado JM, Moñiz-Díez A, Ter Horst R, et al. Polymorphisms within the TNFSF4 and mapkapk2 loci influence the risk of developing invasive aspergillosis: a two-stage case control study in the context of the aspbionics consortium. *J Fungi*. 2021;7:1-17. doi:[10.3390/jof7010004](https://doi.org/10.3390/jof7010004)
 41. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet*. 2009;5:e1000529. doi:[10.1371/journal.pgen.1000529](https://doi.org/10.1371/journal.pgen.1000529)
 42. Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nat Commun*. 2016;7:12050. doi:[10.1038/ncomms12050](https://doi.org/10.1038/ncomms12050)
 43. Bycroft C, Freeman C, Petkova D, et al. The UK biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203-209. doi:[10.1038/s41586-018-0579-z](https://doi.org/10.1038/s41586-018-0579-z)
 44. Mbatchou J, Barnard L, Backman J, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet*. 2021;53:1097-1103. doi:[10.1038/s41588-021-00870-7](https://doi.org/10.1038/s41588-021-00870-7)
 45. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health*. 2019;22:153-160. doi:[10.1136/ebmental-2019-300117](https://doi.org/10.1136/ebmental-2019-300117)
 46. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190-2191. doi:[10.1093/bioinformatics/btq340](https://doi.org/10.1093/bioinformatics/btq340)
 47. Li Y, Oosting M, Smeekens SP, et al. A functional genomics approach to understand variation in cytokine production in humans. *Cell*. 2016;167:1099-1110.e14. doi:[10.1016/j.cell.2016.10.017](https://doi.org/10.1016/j.cell.2016.10.017)
 48. Aguirre-Gamboa R, Joosten I, Urbano PCM, et al. Differential effects of environmental and genetic factors on T and B cell immune traits. *Cell Rep*. 2016;17:2474-2487. doi:[10.1016/j.celrep.2016.10.053](https://doi.org/10.1016/j.celrep.2016.10.053)
 49. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res*. 2016;44:D877-D881. doi:[10.1093/nar/gkv1340](https://doi.org/10.1093/nar/gkv1340)
 50. Sloan CA, Chan ET, Davidson JM, et al. ENCODE data at the ENCODE portal. *Nucleic Acids Res*. 2016;44:D726-D732. doi:[10.1093/nar/gkv1160](https://doi.org/10.1093/nar/gkv1160)
 51. Lonsdale J, Thomas J, Salvatore M, et al. The genotype-tissue expression (GTEx) project. *Nat Genet*. 2013;45:580-585. doi:[10.1089/bio.2015.29031.hmm](https://doi.org/10.1089/bio.2015.29031.hmm)
 52. Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet*. 2013;45:1238-1243. doi:[10.1038/ng.2756](https://doi.org/10.1038/ng.2756)
 53. Da Silva Filho MI, Försti A, Weinhold N, et al. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. *Leukemia*. 2017;31:1735-1742. doi:[10.1038/leu.2016.387](https://doi.org/10.1038/leu.2016.387)

54. Chattopadhyay S, Thomsen H, Weinhold N, et al. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. *Leukemia*. 2020;34:1187-1191. doi:10.1038/s41375-019-0619-1
55. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. *Nat Genet*. 2009;41:677-687. doi:10.1038/ng.384
56. Folkersen L, Van't Hooft F, Chernogubova E, et al. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. *Circ Cardiovasc Genet*. 2010;3:365-373. doi:10.1161/CIRCGENETICS.110.948935
57. Liu M, Xu P, O'Brien T, Shen S. Multiple roles of Ulk4 in neurogenesis and brain function. *Neurogenesis (Austin)*. 2017;4:e1313646. doi:10.1080/23262133.2017.1313646
58. Ardlie KG, DeLuca DS, Segrè AV, et al. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science*. 1979;205(348):648-660. doi:10.1126/science.1262110
59. Pendás-Franco N, Aguilera Ó, Pereira F, González-Sancho JM, Muñoz A. Vitamin D and Wnt/ β -catenin pathway in colon cancer: role and regulation of DICKKOPF genes. *Anticancer Res*. 2008;28:2613-2623. Accessed February 21, 2025. <https://pubmed.ncbi.nlm.nih.gov/19035286/>
60. Rohan JNP, Weigel NL. 1α , 25-dihydroxyvitamin D 3 reduces c-Myc expression, inhibiting proliferation and causing G 1 accumulation in C4-2 prostate cancer cells. *Endocrinology*. 2009;150:2046-2054. doi:10.1210/en.2008-1395
61. Cross HS, Lipkin M, Kállay E. Nutrients regulate the colonic vitamin D system in mice: relevance for human colon malignancy. *J Nutr*. 2006;136:561-564. doi:10.1093/jn/136.3.561
62. Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. *Blood*. 2000;95:1869-1871. Accessed February 21, 2025. <https://pubmed.ncbi.nlm.nih.gov/10688850/>
63. Krishnakumar R, Chen AF, Pantovich MG, et al. FOXD3 regulates pluripotent stem cell potential by simultaneously initiating and repressing enhancer activity. *Cell Stem Cell*. 2016;18:104-117. doi:10.1016/j.stem.2015.10.003
64. Liber D, Domaschenz R, Holmqvist PH, et al. Epigenetic priming of a pre-B cell-specific enhancer through binding of Sox2 and Foxd3 at the ESC stage. *Cell Stem Cell*. 2010;7:114-126. doi:10.1016/j.stem.2010.05.020
65. Sandberg ML, Sutton SE, Pletcher MT, et al. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. *Dev Cell*. 2005;8:153-166. doi:10.1016/j.devcel.2004.12.015
66. Nagel S, Ehrentaut S, Meyer C, Kaufmann M, Drexler HG, MacLeod RAF. Aberrantly expressed OTX homeobox genes deregulate B-cell differentiation in Hodgkin lymphoma. *PLoS One*. 2015;10:e0138416. doi:10.1371/journal.pone.0138416
67. von Wnuck LK, Sattler K, Peters S, et al. Hepatocyte nuclear factor 1A is a cell-intrinsic transcription factor required for B cell differentiation and development in mice. *J Immunol*. 2016;196:1655-1665. doi:10.4049/jimmunol.1500897
68. Kienzler AK, Rizzi M, Reith M, Nutt SL, Eibel H. Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. *J Allergy Clin Immunol*. 2013;131:1695-1699.e9. doi:10.1016/j.jaci.2013.01.018
69. Wong CK, Wade-Vallance AK, Luciani DS, Brindle PK, Lynn FC, Gibson WT. The p300 and CBP transcriptional coactivators are required for β -cell and α -cell proliferation. *Diabetes*. 2018;67:412-422. doi:10.2337/db17-0237
70. He S, Sharpless NE. Senescence in health and disease. *Cell*. 2017;169:1000-1011. doi:10.1016/j.cell.2017.05.015
71. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. *Int J Cancer*. 2012;130:1715-1725. doi:10.1002/ijc.27316
72. Ríos-Tamayo R, Lupiáñez CB, Campa D, et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMENSE consortium and meta-analysis. *Oncotarget*. 2016;7:59029-59048. doi:10.18632/oncotarget.10665
73. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. *Blood*. 1997;89:2500-2506. Accessed February 21, 2025. <https://pubmed.ncbi.nlm.nih.gov/9116295/>
74. Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. *Ann Hematol*. 2010;89:191-199. doi:10.1007/s00277-009-0818-3
75. Yang T, Liu X, Kumar SK, Jin F, Dai Y. Decoding DNA methylation in epigenetics of multiple myeloma. *Blood Rev*. 2022;51:100872. doi:10.1016/j.blre.2021.100872
76. Budina-Kolomets A, Hontz RD, Pimkina J, Murphy ME. A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. *Autophagy*. 2013;9:1553-1565. doi:10.4161/auto.25831
77. Shah V, Boyd KD, Houlston RS, Kaiser MF. Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. *BMC Cancer*. 2017;17:718. doi:10.1186/s12885-017-3715-5
78. Swertz MA, Dijkstra M, Adamusiak T, et al. The MOLGENIS toolkit: rapid prototyping of biosoftware at the push of a button. *BMC Bioinform*. 2010;11(Suppl 12):S12. doi:10.1186/1471-2105-11-S12-S12

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Sánchez-Maldonado JM, Macaudo A, Cabrera-Serrano AJ, et al. *ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance. Int J Cancer*. 2026;1-13. doi:10.1002/ijc.70427